SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as community members discuss its potential involvement with the U.S. government and the strategic importance of its Greenland rare earth deposits. Investors are evaluating the company's increased ownership stake in the Tanbreez project, while some highlight the relationship between CRML and European Lithium (EULIF) and its possible undervaluation. Overall, the conversation centers on CRML's position in the critical minerals sector and potential catalysts for future growth.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as the community rallies around its potential as the 'Bitcoin of memes' and a representation of the entire crypto industry. Discussions highlight the token's timeless narrative centered on Satoshi Nakamoto, the pseudonymous creator of Bitcoin, and its strong community. Some users are celebrating the project's two-year anniversary.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is trending as community members discuss its potential, citing upcoming catalysts and integrations. There's excitement around the sunsetting of $PRQ and anticipation for new exchange listings. Community members highlight the project's utility and low supply, expressing long-term bullish sentiment.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending due to anticipation surrounding potential public flights of its Midnight aircraft at the California International Air Show, sparking community debate on whether the company will demonstrate vertical takeoff capabilities. Some investors express confidence in upcoming catalysts, while others compare Archer's progress and market position to competitors like Joby Aviation. Discussions also include speculation around potential partnerships, particularly with Tesla, and the impact of government shutdowns on FAA approvals.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community emphasizes the cultural significance and longevity of weed culture. Some users are drawing parallels to Bitcoin, while others highlight the coin's potential and encourage others to invest. Community members are sharing links to the Weedcoin website and DEX screeners.

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Amicus Therapeutics Inc

FOLD is trending as investors discuss the potential impact of trial outcomes and settlement possibilities, with community members weighing the likelihood of a deal. Analyst ratings have recently been updated, contributing to the stock's activity. Some see FOLD as undervalued compared to peers, particularly when considering revenue multiples and potential M&A scenarios.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending as the community discusses a potential overreaction to recent trial data and what it means for future FDA approval. Bullish investors are pointing to strong secondary endpoints and a large options contract as signs of an impending rise, while bears cite negative financials and skepticism around the drug's efficacy. Chatter revolves around whether the stock is undervalued and if a potential buyout by Merck could be back on the table.

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Insulet Corporation

Insulet (PODD) is trending amid unusual options activity and community discussion around potential ROI from call options. Some analysts believe recent product approvals may drive growth, while others note bearish put flow, with community members sharing both bullish and bearish sentiments regarding the stock's prospects. The stock has seen impressive gains over the past year, and investors are currently assessing the drivers behind this rally, including international expansion and adoption of its Omnipod 5 system.

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Mind Medicine Inc

Mind Medicine Inc - Ordinary Shares (Sub Voting)

MNMD is trending as community members discuss the company's progress in clinical trials and potential market opportunities in the psychedelic treatment space. Bullish sentiment is fueled by discussions around market capitalization, institutional investment, and upcoming catalysts related to trial readouts and regulatory interactions. Some traders are also noting technical indicators, suggesting a potential for upward price movement.

Valvoline, Inc. engages in the production, marketing, and supply of engine and automotive maintenance products and services. It operates through the Retail Services segment. The Retail Services segment services the passenger car and light truck quick lube market in the US and Canada with preventive maintenance services done through company operated and independent franchise care stores. The company was founded by John Ellis in 1866 and is headquartered in Lexington, KY.

Valvoline Inc

Valvoline is trending as community members discuss the potential for the stock to test all-time highs, driven by planned store openings and expansion into electric vehicle services. Many see it as a safe, long-term hold with financial AI analysis supporting its health. Bullish sentiment is fueled by significant buy orders and expectations for a positive run in the coming weeks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Buy Rating Affirmed for Terns Pharmaceuticals Amid Positive Forecasts for Obesity Drug TERN-601

JMP Securities analyst Silvan Tuerkcan has reiterated their bullish stance on TERN stock, giving a Buy rating on August 21. Silvan Tuerkcan has giv...

Analyst Forecasts Terns Pharmaceuticals' Upcoming CML Trial Data as Catalyst for Growth

Analyst Etzer Darout of BMO Capital reiterated a Buy rating on Terns Pharmaceuticals (TERN Research Report), retaining the price target of $19.00...

Terns Pharmaceuticals Announces Executive Shake-up and Strategic Evolution

An update from Terns Pharmaceuticals (TERN) is now available. Terns Pharmaceuticals, Inc. is undergoing a significant executive restructuring with...

Commit To Purchase Terns Pharmaceuticals At $5, Earn 37.2% Annualized Using Options

Investors considering a purchase of Terns Pharmaceuticals Inc (TERN) stock, but tentative about paying the going market price of 6.72/share, might benefit from considering selling puts among the...

UBS Group Cuts Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $18.00

Terns Pharmaceuticals (NASDAQ:TERN - Free Report) had its price target decreased by UBS Group from $19.00 to $18.00 in a research note released on Wednesday morning, Benzinga reports. UBS Group...

Buy Rating on Terns Pharmaceuticals Amid Promising Developments in Obesity Treatment Sector

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Terns Pharmaceuticals (TERN Research Report) on March 27 and set a price t...

Terns Pharmaceuticals (NASDAQ:TERN) PT Lowered to $18.00

Terns Pharmaceuticals (NASDAQ:TERN  Get Free Report) had its price target reduced by equities research analysts at UBS Group from $19.00 to $18.00 in a report released on Wednesday, Benzinga...

Terns Pharmaceuticals (NASDAQ:TERN) PT Lowered to $15.00

Terns Pharmaceuticals (NASDAQ:TERN  Get Free Report) had its price objective lowered by investment analysts at JMP Securities from $17.00 to $15.00 in a research report issued on Monday...

Terns Pharmaceuticals (NASDAQ:TERN) PT Raised to $19.00

Terns Pharmaceuticals (NASDAQ:TERN  Get Free Report) had its price objective upped by stock analysts at BMO Capital Markets from $18.00 to $19.00 in a research report issued to clients and...

Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Spruce Biosciences (SPRB)

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Terns Pharmaceuticals (TERN Research Report) and Spruce Biosciences...

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

TERN
Terns Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TERN News

TERN Terns Pharmaceuticals Inc